{"id":30685,"date":"2025-08-25T05:54:00","date_gmt":"2025-08-25T05:54:00","guid":{"rendered":"https:\/\/www.hotelsalepage.com\/feed\/cision-pr-newswire\/cambrex-expands-peptide-manufacturing-capabilities-in-waltham-massachusetts\/"},"modified":"2025-08-25T05:54:00","modified_gmt":"2025-08-25T05:54:00","slug":"cambrex-expands-peptide-manufacturing-capabilities-in-waltham-massachusetts","status":"publish","type":"post","link":"https:\/\/thaipropertynews.com\/feeds\/?p=30685","title":{"rendered":"Cambrex Expands Peptide Manufacturing Capabilities in Waltham, Massachusetts"},"content":{"rendered":"\n\n\n
\"\"<\/td>\n\"\"<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

EAST RUTHERFORD, N.J.<\/span><\/span>, Aug. 25, 2025<\/span><\/span> \/PRNewswire\/ — Cambrex, a leading global contract development and manufacturing organization (CDMO), today announced that Snapdragon Chemistry, a Cambrex company, has expanded its active pharmaceutical ingredient (API) facility in Waltham, Massachusetts<\/span> to further support the development and manufacturing of peptide therapies.<\/p>\n

The new GMP manufacturing suite increases the overall facility footprint by 20% and includes an ISO-7 cleanroom for preparative HPLC chromatography and lyophilization, cold storage for raw materials and a product storage suite. With the completion of this investment, Snapdragon can now support peptide projects from development to GMP manufacturing using solid-phase peptide synthesis (SPPS), liquid-phase peptide synthesis (LPPS), or hybrid approaches.<\/p>\n

“We designed this facility with a three-step strategy in mind for the development of peptide drug candidates,” said Dr. Eric Fang<\/span>, General Manager at Snapdragon Chemistry. “We start with automated SPPS technology for proof-of-concept. In parallel, we optimize the process using LPPS technology to accelerate development and reduce manufacturing cost. We can then transfer the process to our large manufacturing facilities, such as Charles City, Iowa<\/span>, to produce materials in traditional large batch reactors, significantly reducing the cost of those drugs.”<\/p>\n

Snapdragon’s LPPS technology utilizes traditional API batch reactors and continuous flow, obviating the dependency on specialized, solid-phase reactors. This new LPPS technology materially reduces solvent demand and the need for excess reagents compared to standard solid-state peptide synthesis processes.<\/p>\n

“SPPS certainly has its place. We use it in early development to get to the clinic and to proof-of-concept quickly, but it’s not a scalable solution if you want to supply a huge patient population,” said Dr. Matt Bio<\/span>, Chief Scientific Officer, Cambrex. “We designed the LPPS process so that we can leverage all 1.4 million Liters of capacity within Cambrex to deliver peptide therapies.”<\/p>\n

Cambrex continues to invest in R&D across complex synthetic modalities, including further innovation for peptide manufacturing, as well as new research on the application of artificial intelligence for the optimization of oligonucleotide processes.<\/p>\n

About Snapdragon Chemistry <\/b><\/p>\n

Snapdragon Chemistry, a Cambrex company, specializes in active pharmaceutical ingredient (API) batch and continuous flow process development, utilizing state-of-the-art automation technology and proprietary equipment to solve complex process and analytical development challenges. With R&D and manufacturing headquartered in Waltham, Massachusetts<\/span>, Snapdragon’s 70+ employees come with strong ties to the local scientific community, with 31 PhD scientists on staff.<\/p>\n

About Cambrex
<\/b>Cambrex is a leading global contract development and manufacturing organization (CDMO) that provides drug substance development and manufacturing across the entire drug lifecycle, as well as comprehensive analytical and IND enabling services.<\/p>\n

With over 40 years of experience and a team of 2,000 experts servicing global clients from North America<\/span> and Europe<\/span>, Cambrex offers a range of specialized drug substance technologies and capabilities, including continuous flow, controlled substances, solid-state science, material characterization, and highly potent APIs.\u00a0<\/p>\n

\u00a0<\/p>","protected":false},"excerpt":{"rendered":"

<\/p>\n\n\n\n
\"\"<\/td>\n\"\"<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

EAST RUTHERFORD, N.J.<\/span><\/span>, Aug. 25, 2025<\/span><\/span> \/PRNewswire\/ — Cambrex, a leading global contract development and manufacturing organization (CDMO), today announced that Snapdragon Chemistry, a Cambrex company, has expanded its active pharmaceutical ingredient (API) facility in Waltham, Massachusetts<\/span> to further support the development and manufacturing of peptide therapies.<\/p>\n

The new GMP manufacturing suite increases the overall facility footprint by 20% and includes an ISO-7 cleanroom for preparative HPLC chromatography and lyophilization, cold storage for raw materials and a product storage suite. With the completion of this investment, Snapdragon can now support peptide projects from development to GMP manufacturing using solid-phase peptide synthesis (SPPS), liquid-phase peptide synthesis (LPPS), or hybrid approaches.<\/p>\n

“We designed this facility with a three-step strategy in mind for the development of peptide drug candidates,” said Dr. Eric Fang<\/span>, General Manager at Snapdragon Chemistry. “We start with automated SPPS technology for proof-of-concept. In parallel, we optimize the process using LPPS technology to accelerate development and reduce manufacturing cost. We can then transfer the process to our large manufacturing facilities, such as Charles City, Iowa<\/span>, to produce materials in traditional large batch reactors, significantly reducing the cost of those drugs.”<\/p>\n

Snapdragon’s LPPS technology utilizes traditional API batch reactors and continuous flow, obviating the dependency on specialized, solid-phase reactors. This new LPPS technology materially reduces solvent demand and the need for excess reagents compared to standard solid-state peptide synthesis processes.<\/p>\n

“SPPS certainly has its place. We use it in early development to get to the clinic and to proof-of-concept quickly, but it’s not a scalable solution if you want to supply a huge patient population,” said Dr. Matt Bio<\/span>, Chief Scientific Officer, Cambrex. “We designed the LPPS process so that we can leverage all 1.4 million Liters of capacity within Cambrex to deliver peptide therapies.”<\/p>\n

Cambrex continues to invest in R&D across complex synthetic modalities, including further innovation for peptide manufacturing, as well as new research on the application of artificial intelligence for the optimization of oligonucleotide processes.<\/p>\n

About Snapdragon Chemistry <\/b><\/p>\n

Snapdragon Chemistry, a Cambrex company, specializes in active pharmaceutical ingredient (API) batch and continuous flow process development, utilizing state-of-the-art automation technology and proprietary equipment to solve complex process and analytical development challenges. With R&D and manufacturing headquartered in Waltham, Massachusetts<\/span>, Snapdragon’s 70+ employees come with strong ties to the local scientific community, with 31 PhD scientists on staff.<\/p>\n

About Cambrex
<\/b>Cambrex is a leading global contract development and manufacturing organization (CDMO) that provides drug substance development and manufacturing across the entire drug lifecycle, as well as comprehensive analytical and IND enabling services.<\/p>\n

With over 40 years of experience and a team of 2,000 experts servicing global clients from North America<\/span> and Europe<\/span>, Cambrex offers a range of specialized drug substance technologies and capabilities, including continuous flow, controlled substances, solid-state science, material characterization, and highly potent APIs.\u00a0<\/p>\n

\u00a0<\/p>\n

<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":[],"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[5,7],"tags":[],"class_list":["post-30685","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cision-pr-newswire","category-cision-pr-newswire-en"],"_links":{"self":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/30685","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=30685"}],"version-history":[{"count":0,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/30685\/revisions"}],"wp:attachment":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=30685"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=30685"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=30685"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}